These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21142776)

  • 1. High levels of women's satisfaction and compliance with transdermal contraception: results from a European multinational, 6-month study.
    Jakimiuk AJ; Crosignani PG; Chernev T; Prilepskaya V; Bergmans P; Von Poncet M; Marelli S; Lee EJ
    Gynecol Endocrinol; 2011 Oct; 27(10):849-56. PubMed ID: 21142776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy.
    Crosignani PG; Nappi C; Ronsini S; Bruni V; Marelli S; Sonnino D;
    BMC Womens Health; 2009 Jun; 9():18. PubMed ID: 19566925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study.
    Weisberg F; Bouchard C; Moreau M; Audet MC; Mawdsley S; Dattani D; Dinniwell J; Horbay GL;
    J Obstet Gynaecol Can; 2005 Apr; 27(4):350-9. PubMed ID: 15937609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.
    Goa KL; Warner GT; Easthope SE
    Treat Endocrinol; 2003; 2(3):191-206. PubMed ID: 15966567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adolescents' experiences using the contraceptive patch versus pills.
    Sucato GS; Land SR; Murray PJ; Cecchini R; Gold MA
    J Pediatr Adolesc Gynecol; 2011 Aug; 24(4):197-203. PubMed ID: 21454110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal hormonal contraception: benefits and risks.
    Burkman RT
    Am J Obstet Gynecol; 2007 Aug; 197(2):134.e1-6. PubMed ID: 17689623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical study of transdermal contraceptive patch in Thai adolescence women.
    Piyasirisilp R; Taneepanichskul S
    J Med Assoc Thai; 2008 Feb; 91(2):137-41. PubMed ID: 18389975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the contraceptive efficacy, compliance, and satisfaction with the transdermal contraceptive patch system Evra: a comparison between adolescent and adult users.
    Bodner K; Bodner-Adler B; Grünberger W
    Arch Gynecol Obstet; 2011 Mar; 283(3):525-30. PubMed ID: 20111970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra).
    Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit
    J Fam Plann Reprod Health Care; 2004 Jan; 30(1):43-5. PubMed ID: 15006313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
    Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
    Gruber D; Skřivánek A; Serrani M; Lanius V; Merz M
    Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol.
    Gauthier A; Upmalis D; Dain MP
    Acta Obstet Gynecol Scand Suppl; 1992; 156():27-32. PubMed ID: 1324554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norelgestromin/ethinyl estradiol transdermal system.
    Taneepanichskul S
    J Med Assoc Thai; 2005 Oct; 88 Suppl 2():S82-4. PubMed ID: 17722322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combined hormonal contraception in cycles artificially extended].
    Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
    Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study.
    Wiegratz I; Bassol S; Weisberg E; Mellinger U; Merz M
    Reprod Sci; 2014 Dec; 21(12):1518-25. PubMed ID: 24784719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a transdermal contraceptive system.
    Smallwood GH; Meador ML; Lenihan JP; Shangold GA; Fisher AC; Creasy GW;
    Obstet Gynecol; 2001 Nov; 98(5 Pt 1):799-805. PubMed ID: 11704172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergic contact dermatitis due to transdermal contraception patch.
    Stricker T; Sennhauser FH
    J Pediatr; 2006 Jun; 148(6):845. PubMed ID: 16769403
    [No Abstract]   [Full Text] [Related]  

  • 19. [Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
    Radowicki S; Skórzewska K; Szlendak K
    Ginekol Pol; 2005 Nov; 76(11):884-9. PubMed ID: 16566363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
    Kaunitz AM; Portman D; Westhoff CL; Archer DF; Mishell DR; Rubin A; Foegh M
    Obstet Gynecol; 2014 Feb; 123(2 Pt 1):295-303. PubMed ID: 24402597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.